drugset / Trial / NCT00245895

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

NCT00245895

Phase 2 Completed 20 enrolled University of Washington Amgen · collab
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to see if darbepoetin alfa is an effective treatment for anemia in prostate cancer patients and, if so, what dose is most effective. Sometimes prostate cancer patients have low red blood cell counts (low hemoglobin) from various treatments they are receiving, such as chemotherapy. The red blood cells deliver oxygen to the tissue. This then helps give the patient more energy.

Timeline

Start
2003-04
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic

Indications